Apraclonidine in the treatment of ptosis

Subhashie Wijemanne, Dhanya Vijayakumar, Joseph Jankovic

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Transient ptosis is a known complication of botulinum toxin (BoNT) injection due to inadvertent migration of toxin into the levator palpebrae superioris muscle. Currently there is no treatment available for BoNT induced ptosis. Apraclonidine hydrochloride is a topical ophthalmic solution with selective alpha-2 and weak alpha-1 receptor agonist activity that has the ability to elevate the eye lid. Apraclonidine has been used as a diagnostic test in Horner's syndrome. We evaluated the effects apraclonidine in a cohort of BoNT induced ptosis and a patient with Horner syndrome. Each patient was administered 2 drops of apraclonidine 0.5% solution to the eye with the ptosis and was re-examined 20–30 min later. All 6 patients showed improvement in ptosis. There was also improvement in ptosis in a patient with Horner's syndrome. Apraclonidine is not only useful as a diagnostic test in Horner's syndrome, but may be an effective and safe treatment for BoNT-induced ptosis.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalJournal of the Neurological Sciences
Volume376
DOIs
StatePublished - May 15 2017
Externally publishedYes

Keywords

  • Apraclonidine
  • Botulinum toxin
  • Horner's syndrome
  • Ptosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Apraclonidine in the treatment of ptosis'. Together they form a unique fingerprint.

Cite this